https://www.selleckchem.com/products/lirafugratinib.html OBJECTIVEThere is not agreement on the "gold standard" for detection and grading of Chemotherapy Induced Peripheral Neurotoxicity (CIPN) in clinical trials. We performed an observational prospective study to assess and compare both patient-based and physician-based methods.METHODSConsecutive patients, aged 18 years or older, candidates for neurotoxic chemotherapy were enrolled in US/EU/Australia. A trained investigator performed physician-based scales (Total Neuropathy Score clinical [©Johns Hopkins University; TNSc], then used to calculate TNS nurse [TNSn]) and supervised the patient-completed questionnaire (FACT/GOG-NTX©). Evaluations were performed before and at the end of chemotherapy. On participants without neuropathy at baseline we assessed the association between TNSc, TNSn and FACT/GOG-NTX. Considering a previously established Minimal Clinically Important Difference (MCID) for FACT/GOG-NTX, we identified participants with and without a clinically important deterioration according to this scale. Then, not possible. Moreover, the FACT/GOG-NTX score can be reduced to 7 items and these items correlate well with the TNSc and TNSn.CLASSIFICATION OF EVIDENCEThis study provides Class III evidence that a patient-completed questionnaire and nurse-assessed scale correlate with a physician-assessed scale. To determine whether severe hypoglycemic and hyperglycemic events are associated with longitudinal dementia risk in older adults with type 1 diabetes. A longitudinal cohort study followed 2,821 members of an integrated healthcare delivery system with type 1 diabetes from 1997-2015. Hypoglycemic and hyperglycemic events requiring emergency room or hospitalization were abstracted from medical records beginning 1/1/1996 through cohort entry. Participants were followed for dementia diagnosis through 9/30/2015. Dementia risk was examined using Cox proportional hazard models adjusted for age (as timescale), sex, race/